Key Takeaways
- • Biotia closed an oversubscribed $9 million financing round with participation from prominent healthcare investors including Tim Barry and Clive Fields, MD (cofounders of VillageMD), alongside venture firms Convergent Ventures, DigitalDx Ventures, and Continuum Health Ventures.
- • The company's flagship BIOTIA-ID Urine Test demonstrates clinical-grade diagnostic accuracy (97% sensitivity, 99% specificity) for identifying pathogens causing recurrent and complicated urinary tract infections, with availability across all 50 U.S. states.
- • Biotia operates as a CLIA-certified diagnostic laboratory in New York City and leverages pathogen genomics combined with artificial intelligence to address unmet needs in infectious disease diagnostics for chronic and difficult-to-treat infections.
- • The company maintains strategic partnerships with Mayo Clinic, Hospital for Special Surgery (HSS), and NASA, positioning it within a network of leading medical institutions and providing validation for its diagnostic platform.
- • As a spinout from the Jacobs Technion-Cornell Institute at Cornell Tech, Biotia combines academic rigor with commercial infrastructure to scale infectious disease diagnostics in the U.S. healthcare market.
Summary
Biotia announced the closing of an oversubscribed $9 million financing round, signaling strong institutional confidence in its clinical metagenomics platform for infectious disease diagnostics. The round attracted a diverse investor syndicate spanning healthcare entrepreneurs, specialized venture capital firms, and angel networks, including Tim Barry and Clive Fields, MD—the cofounders of primary care provider network VillageMD—alongside Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital, Red Bear Angels, and Red Bear Ventures.
The company's core product, the BIOTIA-ID Urine Test, addresses a significant clinical gap in the diagnosis of recurrent and complicated urinary tract infections. The test delivers diagnostic accuracy at clinical-grade standards, with 97% sensitivity and 99% specificity in identifying causative pathogens. This precision is particularly valuable in cases where traditional culture-based diagnostics fail or prove inconclusive, a common challenge in complicated UTI management. The test is currently available to physicians and patients across all 50 U.S. states, indicating successful regulatory clearance and market distribution infrastructure.
Biotia's competitive positioning derives from its integration of pathogen genomics with artificial intelligence, enabling rapid and accurate pathogen identification without reliance on traditional culture methodologies. The company operates a high-complexity, CLIA-certified diagnostic laboratory in New York City, providing the regulatory foundation and operational scale required for clinical laboratory services. Its organizational heritage as a spinout from the Jacobs Technion-Cornell Institute at Cornell Tech reflects academic origins combined with entrepreneurial execution, a structure increasingly common among biotech diagnostic companies.
The company's partnership ecosystem—including Mayo Clinic, Hospital for Special Surgery, and NASA—demonstrates institutional validation and suggests potential expansion into additional infectious disease applications beyond UTI diagnostics. These relationships provide both clinical credibility and potential pathways for future product development and market access.
The company's core product, the BIOTIA-ID Urine Test, addresses a significant clinical gap in the diagnosis of recurrent and complicated urinary tract infections. The test delivers diagnostic accuracy at clinical-grade standards, with 97% sensitivity and 99% specificity in identifying causative pathogens. This precision is particularly valuable in cases where traditional culture-based diagnostics fail or prove inconclusive, a common challenge in complicated UTI management. The test is currently available to physicians and patients across all 50 U.S. states, indicating successful regulatory clearance and market distribution infrastructure.
Biotia's competitive positioning derives from its integration of pathogen genomics with artificial intelligence, enabling rapid and accurate pathogen identification without reliance on traditional culture methodologies. The company operates a high-complexity, CLIA-certified diagnostic laboratory in New York City, providing the regulatory foundation and operational scale required for clinical laboratory services. Its organizational heritage as a spinout from the Jacobs Technion-Cornell Institute at Cornell Tech reflects academic origins combined with entrepreneurial execution, a structure increasingly common among biotech diagnostic companies.
The company's partnership ecosystem—including Mayo Clinic, Hospital for Special Surgery, and NASA—demonstrates institutional validation and suggests potential expansion into additional infectious disease applications beyond UTI diagnostics. These relationships provide both clinical credibility and potential pathways for future product development and market access.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.